Coravax SARS-CoV-2 Vaccine is made from a portion of the SARS-CoV-2 virus. Utilizing the spike protein component of the virus, the vaccine will most likely generate a robust immune response.
Coravax similar to other vaccines uses a 'carrier' vaccine to deliver the vaccine. Coravax uses a killed rabies vaccine that has the spike protein as an added component. An individual vaccinated with Coravax will develop antibodies for both SARS-CoV-2 as well as rabies.
CORAVAX is indicated for the prevention of the SARS-CoV-2 virus which causes COVID-19.
4/7/2020: Thomas Jefferson University researchers have a COVID-19 vaccine candidate that could cover a global need.
5/20/2020: Bharat Biotech joins Thomas Jefferson University in pursuit of a SARS-CoV-2 vaccine
8/28/2020: $508,000 awarded to Thomas Jefferson University to support the development of Coravax